(redirected from Rhegmatogenous Retinal Detachment)
Also found in: Medical, Encyclopedia.
RRDR.R. Donnelley
RRDRed Rock Deli (chips; Australia)
RRDMinistry of Rural Rehabilitation and Development (Afghanistan)
RRDResearch Results Digest (transportation)
RRDRound Robin Database
RRDRow to Row Delay
RRDRotate Right Digit
RRDRoberto Ricci Designs (Italy)
RRDRound Robin Database (a system to store and display time-series data)
RRDRolls-Royce Deutschland (German manufacturer)
RRDRosyth Royal Dockyard (Scotland, UK)
RRDRhegmatogenous Retinal Detachment
RRDRedundancy Rate Distortion (video coding)
RRDRemovable Rigid Disk
RRDRegional Rail Division
RRDRadio Regulatory Department
RRDRegimental Reconnaissance Detachment
RRDRegular Retirement Date (when an AGR officer has 20 years of Active Federal Service)
RRDReplacement Regulating Detachment
RRDReduced Resolution Data
RRDRelease Requirements Document
RRDRecurrence Rate Data
RRDRemoval of Rigid Dressing
RRDResonant Reed Decoder
References in periodicals archive ?
On the basis of clinical indications, they were divided in four groups which included 18 (55%) patients having Rhegmatogenous retinal detachment, 9 (27%) having Macular holes, 3 (9%) with Vitreous hemorrhage and last 3 (9%) having Dislocation of intraocular lens table-I.
Dexamethasone intravitreal implant for the treatment of recalcitrant macular edema after rhegmatogenous retinal detachment repair.
Comparative Study of 27-Gauge versus 25-Gauge Vitrectomy for the Treatment of Primary Rhegmatogenous Retinal Detachment. J Ophthalmol.
Colucciello, "Rhegmatogenous retinal detachment," Physician and Sportsmedicine, vol.
Antiangiogenic isoforms of vascular endothelial growth factor predominate in subretinal fluid of patients with rhegmatogenous retinal detachment and proliferative vitreoretinopathy.
Contributed by ophthalmologists from Europe, the US, and Israel, the 19 chapters address the surgical and nonsurgical management of vitreoretinal disorders, including diabetic retinopathy; diabetic macular edema, with discussion of the use of anti-vascular endothelial growth factor drugs and diagnosis; proliferative diabetic retinopathy; the complications and management of diabetic vitrectomy; retinal venous occlusions; rhegmatogenous retinal detachment, including vitrectomy, scleral buckling materials, and pneumatic retinopexy; the use of prophylaxis for retinal detachment; retinal detachment due to giant tears or dialysis; macular hole surgery; vitrectomy for epiretinal membranes; Irvine-Gass syndrome; and endophthalmitis.
Many factors are identified that might influence the final outcome of scleral buckle surgery (SBS) for rhegmatogenous retinal detachment and include preoperative findings such as: preoperative visual acuity [2-4], patient age [5], anatomical features such as whether macula is attached or detached, duration of macular detachment [2,3], extent of retinal detachment [6], position and number of retinal breaks [2, 4], refraction (myopia, as a predisposing factor for retinal breaks) [7] and formation of proliferative vitreoretinopathy [4].
This process plays a central role in various blinding conditions, which includes rhegmatogenous retinal detachment, proliferative diabetic retinopathy and macular hole formation.
has launched a Phase II clinical trial for INS37217 Ophthalmic (denufosol tetrasodium) for the treatment of rhegmatogenous retinal detachment (RRD).
According to a 1995 report by the American Academy of Ophthalmology, one in 10,000 people has a retina detach because of a tear or break, a condition called rhegmatogenous retinal detachment.